Outcomes are frequently suboptimal for patients with bipolar disorder who are treated with pharmacotherapy alone. Adjunct exercise has the potential to substantially improve acute and long-term outcomes, although how exercise would improve the course of bipolar disorder needs to be elucidated. We propose that exercise may improve mood and functioning by increasing neurogenesis and reducing allostatic load. We review data suggesting that exercise increases levels of brain-derived neurotrophic factor, which in turn increases neurogenesis and decreases allostatic load. Exercise as a psychosocial adjunct for bipolar disorder should be assessed with rigorous randomized clinical trials.

Keywords:
Exercise, Brain-derived neurotrophic factor, Allostatic load, Bipolar disorder
1.
Stathopoulou G, Powers MB, Berry AC, Smits JAJ, Otto MW: Exercise interventions for mental health: a quantitative and qualitative review. Clin Psychol (New York) 2006;13:179–193.
2.
Ng F, Dodd S, Berk M: The effects of physical activity in the acute treatment of bipolar disorder: a pilot study. J Affect Disord 2007;101:259–262.
3.
Hays AE: Effect of an acute bout of aerobic exercise on dehydroepiandrosterone sulphate (DHEAS) in clinically diagnosed bipolar subjects. Diss Abstr Int B Sci Eng 2008;68:5779.
4.
Edenfield TM: Exercise and mood: exploring the role of exercise in regulating stress reactivity in bipolar disorder. Diss Abstr Int B Sci Eng 2008;68:5566.
5.
Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA: Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008;77:219–226.
6.
Fava GA: The decline of pharmaceutical psychiatry and the increasing role of psychological medicine. Psychother Psychosom 2009;78:220–227.
7.
Caffo E, Belaise C, Forresi B: Promoting resilience and psychological well-being in vulnerable life stages. Psychother Psychosom 2008;77:331–336.
8.
Morriss R, Mohammed FA: Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol 2005;19:94–101.
9.
Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, Schlicht P, Kupfer DJ: The prevalence of the metabolic syndrome in patients with schizoaffective disorder – bipolar subtype. Bipolar Disord 2004;6:314–318.
10.
Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE: Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486–491.
11.
Killbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC: Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007;9:443–452.
12.
Waxmonsky JA, Thomas MR, Miklowitz DJ, Allen MH, Wisniewski SR, Zhang H, Ostacher MJ, Fossey MD: Prevalence and correlates of tobacco use in bipolar disorder: Data from the first 2000 participants in the systematic treatment enhancement program. Gen Hosp Psychiatry 2005;27:321–328.
13.
Keck PE, McElroy SL: Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003;64:1426–1435.
14.
McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PEJ, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207–213.
15.
Sylvia LG, Kopeski LM, Mulrooney C, Reid J, Jacob K, Neuhaus EC: Does exercise impact mood? Exercise patterns of patients in a psychiatric partial hospital program. J Psychiatr Pract 2009;15:70–78.
16.
Vega SJ, Struder KK, Wahrmann BV, Schmidt A, Bloch W, Hollmann W: Acute BDNF and cortisol response to low intensity exercise and following ramp incremental exercise to exhaustion in humans. Brain Res 2006;1121:59–65.
17.
Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP: Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res 2001;120:87–95.
18.
Ma Q: Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health. Neurosci Bull 2008;24:265–267.
19.
Duman CH, Schlesinger L, Russell DS, Duman RS: Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res 2008;1199:148–158.
20.
Tang SW, Chu E, Hui T, Helmeste D, Law C: Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci Lett 2008;431:62–65.
21.
Zhao C, Deng W, Gage FH: Mechanisms and functional implications of adult neurogenesis. Cell 2008;132:645–660.
22.
Karpczinski F, Vieta E, Andreazza AC, Frey BN, Gimes FA, Tramontina J, Anna MK, Grassi-Oliveira R, Post RM: Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675–692.
23.
McEwen BS: Mood disorders and allostatic load. Biol Psychiatry 2003;54:200–207.
24.
Ernst C, Olson AK, Pinel JP, Lam RW, Christie BR: Antidepressant effects of exercise: Evidence for an adult-neurogenesis hypothesis? J Psychiatry Neurosci 2006;31:84–91.
25.
van Praag H, Shubert T, Zhao C, Gage FH: Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 2005;25:8680–8685.
26.
Pereira AC, Huddleston DE, Brickman AM, Sosunov AA, Hen R, McKhann GM, Sloan R, Gage FH, Brown TR, Small SA: An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci USA 2007;104:5638–5643.
27.
Cotman CW, Berchtold NC, Christie L: Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 2007;30:464–472.
28.
Binder DK, Scharfman HE: Brain-derived neurotrophic factor. Growth Factors 2004;22:123–131.
29.
Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S: Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 2005;192:348–356.
30.
Schinder AF, Poo M: The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci 2000;23:639–645.
31.
Lu B: BDNF and activity-dependent synaptic modulation. Learn Mem 2003;10:86–98.
32.
Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC: Greater cortical grey matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007;62:7–16.
33.
Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK: Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241–1242.
34.
Bearden CE, Thompson PM, Dutton RA, Frey BN, Peluso MA, Nicoletti M, Dierschke N, Hayashi KM, Klunder AD, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Soares JC: Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology 2008;33:1229–1238.
35.
Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S: New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008;59:201–220.
36.
Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotropic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251–3261.
37.
Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527–532.
38.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–75.
39.
Guillin O, Demily C, Thibaut F: Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 2007;78:377–395.
40.
Licinio J, Dong C, Wong ML: Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry 2009;66:488–497.
41.
Fan J, Sklar P: Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Found Symp 2008;289:60–72; discussion 72–73, 87–93.
42.
Kanazawa T, Glatt SJ, Kia-Keating B, Yoneda H, Tsuang MT: Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007;17:165–170.
43.
Monteleone P, Serritella C, Martiadis V, Maj M: Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008;10:95–100.
44.
Cunha AB, Frey BN, Andrezza AC, Goi JD, Rosa AR, Gonclaves CA, Santin A, Kapczinski F: Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006;398:215–219.
45.
Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V: Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007;61:142–144.
46.
Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW: Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience 2000;101:305–312.
47.
Ding Q, Vaynman S, Akhavan M, Ying Z, Gomez-Pinilla F: Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 2006;140:823–833.
48.
Vaynman S, Ying Z, Gomez-Pinilla F: Interplay between brain-derived neurotrophic factor and signal transduction modulators in the regulation of the effects of exercise on synaptic plasticity. Neuroscience 2003;122:647–657.
49.
Bryan A, Hutchison KE, Seals DR, Allen DL: A transdisciplinary model integrating genetic, physiological, and psychological correlates of voluntary exercise. Health Psychol 2007;26:30–39.
50.
Tramontina JF, Andreazza AC, Kauer-Sant’anna M, Stertz L, Goi J, Chiarani F, Kapczinski F: Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009;452:111–113.
51.
Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E: The use of antidepressants in bipolar disorder. J Clin Psychiatry 2008;69:1307–1318.
52.
Ströhle A, Höfler M, Pfister H, Müller AG, Hoyer J, Wittchen HU, Lieb R: Physical activity and prevalence and incidence of mental disorders in adolescents and young adults. Psychol Med 2007;37:1657–1666.
53.
Molteni R, Calabrese F, Cattaneo A, Mancini M, Gennarelli M, Racagni G, Riva MA: Acute stress responsiveness of the neurotrophin BDNF in the rat hippocampus is modulated by chronic treatment with the antidepressant duloxetine. Neuropsychopharmacology 2009;34:1523–1532.
54.
Kapczinski F, Frey BN, Kauer-Sant’Anna M, Grassi-Oliveira R: Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 2008;8:1101–1113.
55.
Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron 2002;34:13–25.
56.
McEwen BS: Stress, adaptation, and disease: allostasis and allostatic load. Ann NY Acad Sci 1998;840:33–44.
57.
McEwen BS: Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann NY Acad Sci 2004;1032:1–7.
58.
Araya AV, Orellana X, Espinoza J: Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences. Endocrine 2008;33:300–304.
59.
Yamanaka M, Itakura Y, Ono-Kishino M, Tsuchida A, Nakagawa T, Taiji M: Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng 2008;105:395–402.
60.
Tsuchida A, Nonomura T, Nakagwa Y, Itakura Y, Ono-Kishino M, Yamanaka M, Sugaru E, Taiji M, Noguchi H: Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Diabetes Obes Metab 2002;4:262–269.
61.
Chaldakov GN, Fiore M, Hristova MG, Aloe L: Metabotrophic potential of neurotrophins: implication in obesity and related diseases? Med Sci Monit 2003;9:19–21.
62.
Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, Ghenev PI, Aloe L: Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: A role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004;146:279–289.
63.
Chaldakov GN, Fiore M, Stankulov IS, Hristova M, Antonelli A, Manni L, Ghenev PI, Angelucci F, Aloe L: NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem 2001;109:357–360.
64.
Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L: Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. Int J Cardiol 2005;102:169–171.
65.
Anisman H, Merali Z, Hayley S: Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol 2008;85:1–74.
66.
Tsatsoulis A, Fountoulakis S: The protective role of exercise on stress system dysregulation and comorbidities. Ann NY Acad Sci 2006;1083:196–213.
67.
Moreira MM, de Souza HP, Schwingel PA, de Sá CK, Zoppi CC: Effects of aerobic and anaerobic exercise on cardiac risk variables in overweight adults. Arq Bras Cardiol 2008; 91:219–226.
68.
Pescatello LS, Blanchard BE, Van Heest JL, Maresh CM, Gordish-Dressman H, Thompson PD: The metabolic syndrome and the immediate antihypertensive effects of aerobic exercise: a randomized control design. BMC Cardiovasc Disord 2008;8:12–22.
69.
Artham SM, Lavie CJ, Milani RV: Cardiac rehabilitation programs markedly improve high-risk profiles in coronary patients with high psychological distress. South Med J 2008;101:262–267.
70.
Jago R, Wedderkopp N, Kristensen PL, Moller NC, Andersen LB, Cooper AR, Froberg K: Six-year change in youth physical activity and effect of fasting insulin and HOMA-IR. Am J Prev Med 2008;35:604–605.
71.
Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A: Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust NZ J Psychiatry 2007;41:980–989.
72.
Leppämäki SJ, Partonen TT, Hurme J, Haukka JK, Lönnqvist JK: Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry 2002;63:316–321.
73.
Lustman PJ, Clouse RE, Ciechanowski PS, Hirsch IB, Freedland KE: Depression-related hyperglycemia in type 1 diabetes: a mediational approach. Psychosom Med 2005;67:195–199.
74.
Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, Ciechanowski P, Ludman EJ, Bush T, Young B: Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27:2154–2160.
75.
Salvi V, Albert U, Chiarle A, Soreca I, Bogetto F, Maina G: Metabolic syndrome in Italian patients with bipolar disorder. Gen Hosp Psychiatry 2008;30:318–323.
76.
Chue P, Kovacs CS: Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. Bipolar Disord 2003;5:62–79.
77.
Peh AL: Safety monitoring of patients on atypical antipsychotics. Qual Saf Health Care 2008;17:469–472.
78.
Garcia-Portilla MP, Saiz PA, Bascaran MT, Martínez AS, Benabarre A, Sierra P, Torres P, Montes JM, Bousoño M, Bobes J: Cardiovascular risk in patients with bipolar disorder. J Affect Disord 2009;115:302–308.
79.
Campbell S, Macqueen G: The role of hippocampus in the pathophysiology of major depression. Biol Psychiatry 2004;29:417–426.
80.
Brenner JD, Narayan M, Anderson ER, et al: Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115–118.
81.
Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, Hulshoff Pol HE, Kahn RS: Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009, E-pub ahead of print.
82.
Yatham LN, Lyoo IK, Liddle P, Renshaw PF, Wan D, Lam RW, Hwang J: A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naïve first-episode mania. Bipolar Disord 2007;9:693–697.
83.
Strakowski SM, DelBello MP, Zimmerman ME, Getz GE, Mills NP, Ret J, Shear P, Adler CM: Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002;159:1841–1847.
84.
Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF: Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006;8:65–74.
85.
Nehra R, Chakrabarti S, Pradhan BK, Khehra N: Comparison of cognitive functions between first- and multi-episode bipolar affective disorders. J Affect Disord 2006;93:185–192.
86.
Dixon T, Kravariti E, Frith C, Murray RM, McGuire PK: Effect of symptoms on executive function in bipolar illness. Psychol Med 2004;34:811–821.
87.
Wingo AP, Harvey PD, Baldessarini RJ: Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord 2009;11:113–125.
88.
Frodl TS, Koutsouleris N, Bottlender R, Born C, Jäger M, Scupin I, Reiser M, Möller HJ, Meisenzahl EM: Depression-related variation in brain morphology over 3 years: Effects of stress? Arch Gen Psychiatry 2008;65:1156–1165.
89.
Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T, Reiser M, Möller HJ, Meisenzahl EM: Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci 2008;5:423–430.
90.
Yamasue H, Iwanami A, Hirayasu Y, Yamada H, Abe O, Kuroki N, Fukuda R, Tsujii K, Aoki S, Ohtomo K, Kato N, Kasai K: Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res 2004;131:195–207.
91.
Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C: Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 2006;63:139–149.
92.
Scherk H, Backens M, Schneider-Axmann T, Kemmer C, Usher J, Reith W, Falkai P, Gruber O: Neurochemical pathology in hippocampus in euthymic patients with bipolar I disorder. Acta Psychiatr Scand 2008;117:282–288.
93.
Liu L, Schulz SC, Lee S, Reutiman TJ, Fatemi SH: Hippocampal CA1 pyramidal cell size is reduced in bipolar disorder. Cell Mol Neurobiol 2007;27:351–358.
94.
Majer M, Ising M, Künzel H, Binder EB, Holsboer F, Modell S, Zihl J: Impaired divided attention predicts delayed response and risk to relapse in subjects with depressive disorders. Psychol Med 2004;34:1453–1463.
95.
Holmes MK, Erickson K, Luckenbaugh DA, Drevets WC, Bain EE, Cannon DM, Snow J, Sahakian BJ, Manji HK, Zarate CA Jr: A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord 2008;10:806–815.
96.
Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, Czerski PM, Hauser J: Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005;38:166–170.
97.
Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007;144B:820–823.
98.
Post RM: Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007;41:979–990.
99.
Tseng M, Alda M, Xu L, Sun X, Wang JF, Grof P, Turecki G, Rouleau G, Young LT: BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder. J Psychiatry Neurosci 2008;33:449–453.
100.
Johnson L, Andersson-Lundman G, Aberg-Wistedt A, Mathé AA: Age of onset in affective disorder: its correlation with hereditary and psychosocial factors. J Affect Disord 2000;59:139–148.
101.
Paykel ES: Life events and affective disorders. Acta Psychiatr Scand Suppl 2003;418:61–66.
102.
Hammen C: Generation of stress in the course of unipolar depression. J Abnorm Psychol 1991;100:555–561.
103.
Beyer JL, Kuchibhatla M, Cassidy F, Krishnan KR: Stressful life events in older bipolar patients. Int J Geriatr Psychiatry 2008;23:1271–1275.
104.
Cohen AN, Hammen C, Henry RM, Daley SE: Effects of stress and social support on recurrence in bipolar disorder. J Affect Disord 2004;82:143–147.
105.
Kauer-Sant’Anna M, Tramontina J, Andreazza AC, Cereser K, da Costa S, Santin A, Yatham LN, Kapczinski F: Traumatic life events in bipolar disorder: impact on BDNF levels and psychopathology. Bipolar Disord 2007;9:128–135.
106.
Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN: Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust NZ J Psychiatry 2007;41:321–326.
107.
Smith MA, Makino S, Kvetnansky R, Post RM: Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995;15:1768–1777.
108.
Weiss SJ: Neurobiological alterations associated with traumatic stress. Perspect Psychiatr Care 2007;43:114–122.
109.
Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmal C, Hofels S, Zobel A, Illig T, Propping P, Holsboer F, Rietschel N, Nothen MM, Cichon S: Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 2005;58:307–314.
110.
Rybakowski JK: BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008;9:1589–1593.
111.
Frodl T, Schüle C, Schmitt G, Born C, Baghai T, Zill P, Bottlender R, Rupprecht R, Bondy B, Reiser M, Möller HJ, Meisenzahl EM: Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 2007;64:410–416.
112.
Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM: Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002;109:143–148.
113.
Cirulli F, Francia N, Berry A, Aloe L, Alleva E, Suomi SJ: Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates. Neurosci Biobehav Rev 2009;33:573–585.
114.
Nair A, Vadodaria KC, Banerjee S, Benekareddy M, Dias BG, Duman RS, Vaidya VA: Stressor-specific regulation of distinct brain-derived neurotrophic factor transcripts and cyclic AMP response element-binding protein expression in the postnatal and adult rat hippocampus. Neuropsychopharmacology 2007;32:1504–1519.
115.
Pierce RC, Bari AA: The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity. Rev Neurosci 2001;12:95–110.
116.
Kapczinski F, Dias VV, Frey BN, Kauer-Sant’Anna M: Brain-derived neurotrophic factor in bipolar disorder: beyond trait and state: comment on ‘Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders’. Bipolar Disord 2009;11:221–222.
117.
American College of Sports Medicine: ACSM’S Guidelines for Exercise Testing and Prescription. Baltimore, Lippincott Williams & Wilkins, 2005.
118.
Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, Waugh R, Napolitano MA, Forman LM, Appelbaum M, Doraiswamy PM, Krishnan KR: Effects of exercise training on older patients with major depression. Arch Intern Med 1999;159:2349–2356.
119.
Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, Craighead WE, Baldewicz TT, Krishnan KR: Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000;62:633–638.
120.
Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, Herman S, Craighead WE, Brosse AL, Waugh R, Hinderliter A, Sherwood A: Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med 2007;69:587–596.
121.
Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO: Exercise treatment for depression: efficacy and dose response. Am J Prev Med 2005;28:1–8.
122.
Otto MW, Church TS, Craft LL, Greer TL, Smits JA, Trivedi MH: Exercise for mood and anxiety disorders. J Clin Psychiatry 2007;68:669–676.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.